Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/111812 |
Resumo: | Background: Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluated EGFR mutation profile as well as the presence of mutations in hotspots of KRAS and BRAF in ESCC patients. Methods: We performed RT-qPCR, immunohistochemistry and Fluorescent in situ hybridization to determine EGFR and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism analysis. Results: Our results showed an increased EGFR mRNA expression in tumors compared to surrounding tissue (p <0.05), with 11% of the cases presenting at least a four-fold difference between tumor and paired adjacent mucosa. EGFR protein overexpression was present only in 4% of the cases. The median expression of HER2 mRNA was not different between tumors and adjacent mucosa. Still, 7% of the tumors presented at least a 25-fold higher expression of this gene when compared to its paired counterpart. Immunohistochemical analysis revealed that 21% of the tumors were positive for HER2 (scores 2+ and 3+), although only 3+ tumors presented amplification of this gene. Mutation analysis for EGFR (exons 18-21), KRAS (codons 12 and 13) and BRAF (V600E) showed no mutations in any of the hotspots of these genes in almost 100 patients analyzed. EGFR presented synonymous polymorphisms at codon 836 (C>T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC patients. The absence of mutations of EGFR, KRAS and BRAF as well as the overexpression of EGFR and HER2 in less than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with ESCC. Conclusion: HER receptors target therapies may have the potential to be effective in only a minor fraction of patients with ESCC. |
id |
UFRGS-2_b86e035910c85d0601ab246f198e5667 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/111812 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Gonzaga, Isabela MartinsLima, Sheila Coelho SoaresSantos, Paulo Thiago de SouzaBlanco, Tania Cristina MoitaReis, Bruno de Souza BianchiQuintella, Danielle CarvalhoOliveira, Ivanir Martins deFaria, Paulo Antonio Silvestre deKruel, Cleber Dario PintoAndreollo, Nelson AdamiSimão, Tatiana de AlmeidaPinto, Luis Felipe Ribeiro2015-03-07T01:56:59Z20121471-2407http://hdl.handle.net/10183/111812000952985Background: Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluated EGFR mutation profile as well as the presence of mutations in hotspots of KRAS and BRAF in ESCC patients. Methods: We performed RT-qPCR, immunohistochemistry and Fluorescent in situ hybridization to determine EGFR and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism analysis. Results: Our results showed an increased EGFR mRNA expression in tumors compared to surrounding tissue (p <0.05), with 11% of the cases presenting at least a four-fold difference between tumor and paired adjacent mucosa. EGFR protein overexpression was present only in 4% of the cases. The median expression of HER2 mRNA was not different between tumors and adjacent mucosa. Still, 7% of the tumors presented at least a 25-fold higher expression of this gene when compared to its paired counterpart. Immunohistochemical analysis revealed that 21% of the tumors were positive for HER2 (scores 2+ and 3+), although only 3+ tumors presented amplification of this gene. Mutation analysis for EGFR (exons 18-21), KRAS (codons 12 and 13) and BRAF (V600E) showed no mutations in any of the hotspots of these genes in almost 100 patients analyzed. EGFR presented synonymous polymorphisms at codon 836 (C>T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC patients. The absence of mutations of EGFR, KRAS and BRAF as well as the overexpression of EGFR and HER2 in less than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with ESCC. Conclusion: HER receptors target therapies may have the potential to be effective in only a minor fraction of patients with ESCC.application/pdfengBMC cancer. London. Vol. 2012 (Dec. 2012), 10p.Neoplasias esofágicasGenes erbB-1Receptor erbB-2Terapia de alvo molecularEsophageal cancerEGFRHER2KRASBRAFTarget therapyAlterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomasEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000952985.pdf000952985.pdfTexto completo (inglês)application/pdf2265411http://www.lume.ufrgs.br/bitstream/10183/111812/1/000952985.pdfbc3f9cab1167275f10bb83b7191735ddMD51TEXT000952985.pdf.txt000952985.pdf.txtExtracted Texttext/plain46666http://www.lume.ufrgs.br/bitstream/10183/111812/2/000952985.pdf.txt86d55099654699cf6b9b5fee2694989aMD52THUMBNAIL000952985.pdf.jpg000952985.pdf.jpgGenerated Thumbnailimage/jpeg1705http://www.lume.ufrgs.br/bitstream/10183/111812/3/000952985.pdf.jpgceb8ed6f410fdad2fe8e4d354489f1daMD5310183/1118122018-10-24 08:52:09.127oai:www.lume.ufrgs.br:10183/111812Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2018-10-24T11:52:09Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
title |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
spellingShingle |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas Gonzaga, Isabela Martins Neoplasias esofágicas Genes erbB-1 Receptor erbB-2 Terapia de alvo molecular Esophageal cancer EGFR HER2 KRAS BRAF Target therapy |
title_short |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
title_full |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
title_fullStr |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
title_full_unstemmed |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
title_sort |
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas |
author |
Gonzaga, Isabela Martins |
author_facet |
Gonzaga, Isabela Martins Lima, Sheila Coelho Soares Santos, Paulo Thiago de Souza Blanco, Tania Cristina Moita Reis, Bruno de Souza Bianchi Quintella, Danielle Carvalho Oliveira, Ivanir Martins de Faria, Paulo Antonio Silvestre de Kruel, Cleber Dario Pinto Andreollo, Nelson Adami Simão, Tatiana de Almeida Pinto, Luis Felipe Ribeiro |
author_role |
author |
author2 |
Lima, Sheila Coelho Soares Santos, Paulo Thiago de Souza Blanco, Tania Cristina Moita Reis, Bruno de Souza Bianchi Quintella, Danielle Carvalho Oliveira, Ivanir Martins de Faria, Paulo Antonio Silvestre de Kruel, Cleber Dario Pinto Andreollo, Nelson Adami Simão, Tatiana de Almeida Pinto, Luis Felipe Ribeiro |
author2_role |
author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Gonzaga, Isabela Martins Lima, Sheila Coelho Soares Santos, Paulo Thiago de Souza Blanco, Tania Cristina Moita Reis, Bruno de Souza Bianchi Quintella, Danielle Carvalho Oliveira, Ivanir Martins de Faria, Paulo Antonio Silvestre de Kruel, Cleber Dario Pinto Andreollo, Nelson Adami Simão, Tatiana de Almeida Pinto, Luis Felipe Ribeiro |
dc.subject.por.fl_str_mv |
Neoplasias esofágicas Genes erbB-1 Receptor erbB-2 Terapia de alvo molecular |
topic |
Neoplasias esofágicas Genes erbB-1 Receptor erbB-2 Terapia de alvo molecular Esophageal cancer EGFR HER2 KRAS BRAF Target therapy |
dc.subject.eng.fl_str_mv |
Esophageal cancer EGFR HER2 KRAS BRAF Target therapy |
description |
Background: Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluated EGFR mutation profile as well as the presence of mutations in hotspots of KRAS and BRAF in ESCC patients. Methods: We performed RT-qPCR, immunohistochemistry and Fluorescent in situ hybridization to determine EGFR and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism analysis. Results: Our results showed an increased EGFR mRNA expression in tumors compared to surrounding tissue (p <0.05), with 11% of the cases presenting at least a four-fold difference between tumor and paired adjacent mucosa. EGFR protein overexpression was present only in 4% of the cases. The median expression of HER2 mRNA was not different between tumors and adjacent mucosa. Still, 7% of the tumors presented at least a 25-fold higher expression of this gene when compared to its paired counterpart. Immunohistochemical analysis revealed that 21% of the tumors were positive for HER2 (scores 2+ and 3+), although only 3+ tumors presented amplification of this gene. Mutation analysis for EGFR (exons 18-21), KRAS (codons 12 and 13) and BRAF (V600E) showed no mutations in any of the hotspots of these genes in almost 100 patients analyzed. EGFR presented synonymous polymorphisms at codon 836 (C>T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC patients. The absence of mutations of EGFR, KRAS and BRAF as well as the overexpression of EGFR and HER2 in less than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with ESCC. Conclusion: HER receptors target therapies may have the potential to be effective in only a minor fraction of patients with ESCC. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2015-03-07T01:56:59Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/111812 |
dc.identifier.issn.pt_BR.fl_str_mv |
1471-2407 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000952985 |
identifier_str_mv |
1471-2407 000952985 |
url |
http://hdl.handle.net/10183/111812 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
BMC cancer. London. Vol. 2012 (Dec. 2012), 10p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/111812/1/000952985.pdf http://www.lume.ufrgs.br/bitstream/10183/111812/2/000952985.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/111812/3/000952985.pdf.jpg |
bitstream.checksum.fl_str_mv |
bc3f9cab1167275f10bb83b7191735dd 86d55099654699cf6b9b5fee2694989a ceb8ed6f410fdad2fe8e4d354489f1da |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
lume@ufrgs.br |
_version_ |
1817724949835546624 |